Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US0029421007
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01223DLB2
AARD
Aardvark Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Software - Application · THEMEFOLIO: $HLTH
NAME
Aardvark Therapeutics Inc
ISIN
US0029421007
TICKER
AARD
MIC
XNAS
REUTERS
AARD.OQ
BLOOMBERG
AARD US
Sa., 28.02.2026       Aardvark Therapeutics
US0029421007

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or f...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Aardvark Therapeutics
US0029421007

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimin...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.02.2026       Aardvark Therapeutics
US0029421007

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       Aardvark Therapeutics
US0029421007

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 13.11.2025       Aardvark Therapeutics
US0029421007

Q32025 Earnings...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 11.11.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, 2025, one new employee was gra...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Aardvark Therapeutics
US0029421007

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape ...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 03.11.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that (i) on October 20, 2025, one new employee was granted an inducement award consisting o...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 23.09.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the Stifel 2025 Virtual Cardiome...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 13.08.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the second quarter ended June...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.08.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced new positive preclinical data demonstrating the pot...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 18.07.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that between July 8-14, 2025, two new employees were granted inducement awards consisting o...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.06.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 19.05.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointments of key members of its leadership te...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 14.05.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 3...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 31.03.2025       Aardvark Therapeutics
US0029421007

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December...
Zur Nachricht
Aardvark Therapeutics
Charts & Research Termsheets Terminal
Permalink